Traders Buy Large Volume of Inventiva Call Options (NASDAQ:IVA)

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw some unusual options trading on Wednesday. Investors bought 40,232 call options on the stock. This represents an increase of approximately 201,060% compared to the typical daily volume of 20 call options.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Finally, Truist Financial initiated coverage on shares of Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inventiva has an average rating of “Buy” and an average target price of $16.56.

Inventiva Stock Performance

IVA stock traded down $0.09 during midday trading on Wednesday, hitting $3.69. The company’s stock had a trading volume of 1,724,725 shares, compared to its average volume of 556,902. Inventiva has a 12 month low of $2.85 and a 12 month high of $7.98. The firm’s 50-day moving average is $4.62 and its 200-day moving average is $5.33.

Inventiva (NASDAQ:IVA) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter. As a group, research analysts forecast that Inventiva will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inventiva

Several institutional investors and hedge funds have recently bought and sold shares of IVA. Creative Planning acquired a new stake in Inventiva in the 2nd quarter worth about $32,000. Virtu Financial LLC purchased a new stake in shares of Inventiva in the 4th quarter valued at approximately $60,000. XTX Topco Ltd acquired a new stake in Inventiva during the fourth quarter worth $84,000. Cerity Partners LLC purchased a new stake in Inventiva in the 4th quarter valued at about $93,000. Finally, NewEdge Advisors LLC purchased a new stake in Inventiva in the third quarter valued at approximately $116,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.